Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
|Videos|July 8, 2021
Kenton H. Steele, Esq, on the issues addressed by expert witnesses in medical malpractice litigation
Author(s)Urology Times staff
“There are a couple of different important and unique questions that expert witnesses help answer in the context of medical malpractice litigation,” says Kenton H. Steele, Esq.
Advertisement
In this video, Kenton H. Steele, Esq, continues his overview of expert witnesses in malpractice cases. Steele is an attorney in the Columbus, Ohio office of Reminger Co., LPA and specializes in malpractice defense and insurance litigation.
Advertisement
Related to this article
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
2
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
3
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
4
Closing Risk Stratification Gaps in Localized Prostate Cancer With AI
5